CJC-1295 without DAC side effects and safety context

The honest answer to "what are the side effects" is that nobody has measured them. FDA's 2024 evaluation states that no clinical safety information was submitted or found for CJC-1295 free base — the substance sold as the no-DAC version — and that a search of the FAERS adverse-event database through June 2024 for all CJC-1295-related substances returned only two reports, both excluded for insufficient information or for containing no adverse event at all (FDA briefing document, PCAC December 2024). Two useless reports is not a clean safety record; it is an empty file.

The effects people describe — flushing, headache, a warm or itchy injection site — track what was documented for the long-acting version in healthy volunteers, where injection-site irritation, erythema, induration, pain or itching occurred in roughly 70% of dosed subjects in one study and in all dosed subjects in another; headache in 63% versus 14% on placebo; and flushing, warmth and transient hypotension in about 30%, typically within 30 minutes and resolving within one to two hours (FDA 2024, summarising Teichman et al. 2006).

Vasodilatory flushing in particular is a well-documented signature of the GHRH family rather than an idiosyncrasy of one analogue: in the original healthy-volunteer comparison of GHRH with a growth hormone releasing peptide, mild facial flushing lasting one to three minutes occurred in 16 of 18 men given GHRH(1-44) and in none given the GHRP (Bowers et al., J Clin Endocrinol Metab 1990). A short-acting GHRH analogue would be expected to reproduce that; nobody has published the observation.

One transfer that does not hold is the DAC version's animal toxicology. The injection-site haemorrhage, inflammation and necrosis seen in rats and dogs, and the genotoxic signals reported in mouse pituitary cell cultures, were all recorded with CJC-1295 DAC. FDA's reviewers were explicit that the DAC form's pharmacology cannot be extrapolated to the version without it — which cuts both ways, and means those specific findings are not evidence against the no-DAC form any more than the DAC form's trials are evidence for it.

A category of risk here has nothing to do with pharmacology. FDA evaluated five distinct CJC-1295-related bulk substances and concluded they are "not well characterized" from a physicochemical perspective, citing inconsistent naming conventions across suppliers and registries — including a Global Substance Registration System entry that files the DAC structure under the free base's name.

In practice this means a vial labelled CJC-1295 may contain the short-acting peptide, the long-acting one, or a different salt form with different solubility and stability. The consequences are not symmetrical: someone dosing a weekly-interval protocol who actually received the short-acting peptide gets very little, while someone dosing daily who actually received the DAC form accumulates a compound with a half-life of nearly a week. Peptides are also sensitive to pH, temperature and formulation in ways that drive aggregation and degradation — the attributes that determine immunogenicity risk in an injected product, and the ones a certificate of analysis reporting purity alone does not cover.

If the compound does what it is sold as doing, it inherits the warnings on approved growth hormone labels. FDA said it "has not identified data or information to suggest" that CJC-1295 forms would not present similar risks, and listed them: increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism and pancreatitis.

The one long-term human dataset in the wider secretagogue class points the same way. A review of growth hormone secretagogues found them generally well tolerated in short studies but singled out increases in blood glucose driven by falling insulin sensitivity, and called explicitly for evaluation of cancer incidence and mortality with long-term use (Sigalos & Pastuszak, Sex Med Rev 2018). Fluid retention and joint aching track GH elevation itself, so they are plausible with any compound that raises it effectively.

• Carcinogenicity — no two-year study exists for any CJC-1295 form. Because transgenic mice overexpressing human GHRH develop pituitary hyperplasia and tumours, FDA judged that the same possibility with long-term dosing "cannot be ruled out."
• Reproductive and developmental safety — one abstract-only rat study of the DAC form; nothing covering a full reproductive cycle, and nothing at all on the no-DAC form.
• Paediatric exposure — no safety information on any evaluated substance in children.
• Chronic dosing — the longest published human exposure to any CJC-1295 form is a few weeks in healthy adults.

In December 2024 the Pharmacy Compounding Advisory Committee voted 13–0 against placing CJC-1295 free base on the 503A list of substances usable in compounded medicines; the minutes record that the committee "unanimously agreed" it should not be included, with one member commenting on the lack of evidence for effectiveness (PCAC final summary minutes, 4 December 2024).

See also benefits and areas of research and dosing education.